top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Journal of Health and Medical Sciences

ISSN 2622-7258

Screen Shot 2018-08-12 at 1.24.09 AM.png
Screen Shot 2018-08-12 at 1.24.02 AM.png
Screen Shot 2018-08-12 at 1.23.57 AM.png
Screen Shot 2018-08-12 at 1.23.52 AM.png
open access

Published: 22 September 2022

Guillain-Barré Syndrome: A Case Report of Post Covid-19 Vaccination in the Philippines

Paul Nichol G. Gonzales, Steven G. Villaraza, Aubrey M. Punzalan-Sotelo

Jose R. Reyes Memorial Medical Center

journal of social and political sciences
pdf download

Download Full-Text Pdf



Pages: 276-282

Keywords: Guillain-Barre, Covid-19, Vaccination


Guillain-Barré Syndrome (GBS) is a complex autoimmune disorder where a person’s own immune system damages the nerve and is usually characterized by ascending symmetrical weakness of the upper and lower extremities (Wijdicks & Klein, 2017). It is a rare condition and the worldwide frequency of GBS is only 2 in 100,000 adult individuals (McGrogan et al., 2009). Studies have shown its association with different vaccines but in these pandemic times, there is a lack of literature on post-COVID-19 vaccination-associated GBS. We report a case of a 68-year-old male from Caloocan City with an initial complaint of febrile illness followed by distal lower extremity weakness which started seven (7) days after the patient received his first Sinovac-CoronaVac vaccine. We report a case of GBS that is related to the Sinovac-CoronaVac vaccine which adds to the body of literature that is currently available and may reflect a possible link.


  1. Forsberg, A., Press, R., Einarsson, U., de Pedro-Cuesta, J., & Widén Holmqvist, L. (2004). Impairment in Guillain–Barré syndrome during the first 2 years after onset: A prospective study. Journal of the Neurological Sciences, 227(1), 131–138.

  2. Haber, P., Sejvar, J., Mikaeloff, Y., & DeStefano, F. (2009). Vaccines and Guillain-Barré Syndrome: Drug Safety, 32(4), 309–323.

  3. Hughes, R. A. C. (1990). Pathology of Guillain-Barré Syndrome. In M. Swash (Ed.), Guillain-Barré Syndrome (pp. 83–100). Springer London.

  4. Hughes, R. A., & Cornblath, D. R. (2005). Guillain-Barré syndrome. The Lancet, 366(9497), 1653–1666.

  5. Hughes, R. A., Swan, A. V., van Koningsveld, R., & van Doorn, P. A. (2006). Corticosteroids for Guillain-Barré syndrome. In The Cochrane Collaboration (Ed.), Cochrane Database of Systematic Reviews (p. CD001446.pub2). John Wiley & Sons, Ltd.

  6. Khan, Z., Ahmad, U., Ualiyeva, D., Amissah, O. B., Khan, A., Noor, Z., & Zaman, N. (2022). Guillain-Barre syndrome: An autoimmune disorder post-COVID-19 vaccination? Clinical Immunology Communications, 2, 1–5.

  7. Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., Kusunoki, S., Pardo, C. A., Reisin, R., Sejvar, J. J., Shahrizaila, N., Soares, C., Umapathi, T., Wang, Y., Yiu, E. M., … Jacobs, B. C. (2019). Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology, 15(11), 671–683.

  8. McGrogan, A., Madle, G. C., Seaman, H. E., & de Vries, C. S. (2009). The Epidemiology of Guillain-Barré Syndrome Worldwide. Neuroepidemiology, 32(2), 150–163.

  9. Miravalle, A., Biller, J., Schnitzler, E., & Bonwit, A. (2010). Neurological complications following vaccinations. Neurological Research, 32(3), 285–292.

  10. Omer, S. B., Yildirim, I., & Forman, H. P. (2020). Herd Immunity and Implications for SARS-CoV-2 Control. JAMA, 324(20), 2095.

  11. Salmon, D. A., Proschan, M., Forshee, R., Gargiullo, P., Bleser, W., Burwen, D. R., Cunningham, F., Garman, P., Greene, S. K., Lee, G. M., Vellozzi, C., Yih, W. K., Gellin, B., & Lurie, N. (2013). Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: A meta-analysis. The Lancet, 381(9876), 1461–1468.

  12. Sejvar, J. J., Kohl, K. S., Gidudu, J., Amato, A., Bakshi, N., Baxter, R., Burwen, D. R., Cornblath, D. R., Cleerbout, J., Edwards, K. M., Heininger, U., Hughes, R., Khuri-Bulos, N., Korinthenberg, R., Law, B. J., Munro, U., Maltezou, H. C., Nell, P., Oleske, J., … Wiznitzer, M. (2011). Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 29(3), 599–612.

  13. Shao, S.-C., Wang, C.-H., Chang, K.-C., Hung, M.-J., Chen, H.-Y., & Liao, S.-C. (2021). Guillain-​Barré Syndrome Associated with COVID-19 Vaccination. Emerging Infectious Diseases, 27(12), 3175–3178.

  14. Visser, L., van der Meche, F., Meulstee, J., van Doorn, P., & the Dutch Guillain-Barre study group. (1998). Risk factors for treatment related clinical fluctuations in Guillain-Barre syndrome. Journal of Neurology, Neurosurgery & Psychiatry, 64(2), 242–244.

  15. Waheed, S., Bayas, A., Hindi, F., Rizvi, Z., & Espinosa, P. S. (2021). Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus.

  16. Walgaard, C., Lingsma, H. F., Ruts, L., van Doorn, P. A., Steyerberg, E. W., & Jacobs, B. C. (2011). Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology, 76(11), 968–975.

  17. Wijdicks, E. F. M., & Klein, C. J. (2017). Guillain-Barré Syndrome. Mayo Clinic Proceedings, 92(3), 467–479.

bottom of page